Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
DeLLpro-300
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
- NCT04702737 ↗
- Completed
- Amgen
- Focused
We haven't built an HCP commentary report on DeLLpro-300 (tarlatamab in de novo or treatment emergent neuroendocrine prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DeLLpro-300 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Neuroendocrine Prostate Cancer
- Interventions
- Tarlatamab
- Arms
- Part 1: Dose Exploration · Experimental
- Part 2: Dose Expansion · Experimental
- Enrollment
- 41
- Primary outcomes
- Number of Participants Who Experienced One or More Treatment-emergent Adverse Events (TEAEs)
- Number of Participants Who Experienced One or More Treatment-related Adverse Events (TRAE)
- Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)
- Sponsor
- Amgen
- Start
- Jun 10, 2021
- Primary completion
- Jul 22, 2024
- Results posted
- Yes
- Registry record
- NCT04702737 · updated Sep 12, 2025
Publications
linked from the registry- Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, Horvath L, Greil R, O'Neil B, Siddiqui BA, Bauernhofer T, Bilen MA, Eskens F, Sandhu S, Shaw C, Ju CH, Decato BE, Yu B, Aparicio A. Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clin Cancer Res. 2025 Sep 15;31(18):3854-3863. doi: 10.1158/1078-0432.CCR-25-1211. PubMed 40689871